These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 39217995)
21. Frailty identified by geriatric assessment is associated with poor functioning, high symptom burden and increased risk of physical decline in older cancer patients: Prospective observational study. Kirkhus L; Šaltytė Benth J; Grønberg BH; Hjermstad MJ; Rostoft S; Harneshaug M; Selbæk G; Wyller TB; Jordhøy MS Palliat Med; 2019 Mar; 33(3):312-322. PubMed ID: 30712456 [TBL] [Abstract][Full Text] [Related]
22. Longitudinal changes of health-related quality of life over 10 years in breast cancer patients treated with radiotherapy following breast-conserving surgery. Gao Y; Rosas JC; Fink H; Behrens S; Chang-Claude J; Seibold P Qual Life Res; 2023 Sep; 32(9):2639-2652. PubMed ID: 37093543 [TBL] [Abstract][Full Text] [Related]
23. Modifiable factors affecting older patients' quality of life and physical function during cancer treatment. Kirkhus L; Harneshaug M; Šaltytė Benth J; Grønberg BH; Rostoft S; Bergh S; Hjermstad MJ; Selbæk G; Wyller TB; Kirkevold Ø; Borza T; Saltvedt I; Jordhøy MS J Geriatr Oncol; 2019 Nov; 10(6):904-912. PubMed ID: 31444088 [TBL] [Abstract][Full Text] [Related]
24. Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review. El Alami Y; Essangri H; Majbar MA; Boutayeb S; Benamr S; El Malki HO; Souadka A BMC Cancer; 2021 Jan; 21(1):99. PubMed ID: 33499819 [TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in older hematological cancer survivors (70+) compared to older general population-A German cancer-register-based cross-sectional comparative study. Schatz F; Mehnert-Theuerkauf A; Platzbecker U; Springer F; Götze H Eur J Haematol; 2024 Nov; 113(5):693-703. PubMed ID: 39090028 [TBL] [Abstract][Full Text] [Related]
26. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study. de Ligt KM; Aaronson NK; Liegl G; Nolte S; Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427 [TBL] [Abstract][Full Text] [Related]
27. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry. Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435 [TBL] [Abstract][Full Text] [Related]
28. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758 [TBL] [Abstract][Full Text] [Related]
29. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040 [TBL] [Abstract][Full Text] [Related]
30. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals. Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM; BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611 [TBL] [Abstract][Full Text] [Related]
31. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample. Park KU Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191 [TBL] [Abstract][Full Text] [Related]
32. Normative data for the EORTC QLQ-C30 from the Austrian general population. Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B; Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854 [TBL] [Abstract][Full Text] [Related]
33. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition. Arraras JI; Nolte S; Liegl G; Rose M; Manterola A; Illarramendi JJ; Zarandona U; Rico M; Teiejria L; Asin G; Hernandez I; Barrado M; Vera R; Efficace F; Giesinger JM; Health Qual Life Outcomes; 2021 Aug; 19(1):208. PubMed ID: 34461909 [TBL] [Abstract][Full Text] [Related]
34. Geriatric screening tools are of limited value to predict decline in functional status and quality of life: results of a cohort study. Deckx L; van den Akker M; Daniels L; De Jonge ET; Bulens P; Tjan-Heijnen VC; van Abbema DL; Buntinx F BMC Fam Pract; 2015 Mar; 16():30. PubMed ID: 25888485 [TBL] [Abstract][Full Text] [Related]
35. Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15. Johnson C; Fitzsimmons D; Gilbert J; Arrarras JI; Hammerlid E; Bredart A; Ozmen M; Dilektasli E; Coolbrandt A; Kenis C; Young T; Chow E; Venkitaraman R; Howse F; George S; O'Connor S; Yadegarfar G; Eur J Cancer; 2010 Aug; 46(12):2242-52. PubMed ID: 20580993 [TBL] [Abstract][Full Text] [Related]
36. Health-Related Quality of Life in Danish Cancer Survivors Referred to a Late Effects Clinic: A Prospective Cohort Study. Tolstrup LK; Dieperink KB; Van Leeuwen M; Möller S; Fechner L; Clausen LH; Mattsson TO Acta Oncol; 2024 Jun; 63():426-432. PubMed ID: 38881340 [TBL] [Abstract][Full Text] [Related]
37. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values. Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722 [TBL] [Abstract][Full Text] [Related]
38. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155 [TBL] [Abstract][Full Text] [Related]
39. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777 [TBL] [Abstract][Full Text] [Related]
40. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]